TW202511485A - 調節rps25基因之表現及/或其功能的反義寡核苷酸 - Google Patents

調節rps25基因之表現及/或其功能的反義寡核苷酸 Download PDF

Info

Publication number
TW202511485A
TW202511485A TW113122108A TW113122108A TW202511485A TW 202511485 A TW202511485 A TW 202511485A TW 113122108 A TW113122108 A TW 113122108A TW 113122108 A TW113122108 A TW 113122108A TW 202511485 A TW202511485 A TW 202511485A
Authority
TW
Taiwan
Prior art keywords
antisense oligonucleotide
stranded antisense
nucleic acid
acceptable salt
pharmaceutically acceptable
Prior art date
Application number
TW113122108A
Other languages
English (en)
Chinese (zh)
Inventor
青山智彦
浅野成宏
角谷友美
川野邊峻哲
阿賈亞 拉姆 什雷斯塔
鈴木高尾
Original Assignee
日商住友製藥股份有限公司
日商璐庫薩那生物技術股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商住友製藥股份有限公司, 日商璐庫薩那生物技術股份有限公司 filed Critical 日商住友製藥股份有限公司
Publication of TW202511485A publication Critical patent/TW202511485A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW113122108A 2023-06-16 2024-06-14 調節rps25基因之表現及/或其功能的反義寡核苷酸 TW202511485A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2023-099439 2023-06-16
JP2023099439 2023-06-16

Publications (1)

Publication Number Publication Date
TW202511485A true TW202511485A (zh) 2025-03-16

Family

ID=93852230

Family Applications (1)

Application Number Title Priority Date Filing Date
TW113122108A TW202511485A (zh) 2023-06-16 2024-06-14 調節rps25基因之表現及/或其功能的反義寡核苷酸

Country Status (5)

Country Link
EP (1) EP4729616A1 (cg-RX-API-DMAC7.html)
JP (1) JPWO2024257847A1 (cg-RX-API-DMAC7.html)
CN (1) CN121311591A (cg-RX-API-DMAC7.html)
TW (1) TW202511485A (cg-RX-API-DMAC7.html)
WO (1) WO2024257847A1 (cg-RX-API-DMAC7.html)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1015469B2 (en) 1997-09-12 2015-11-18 Exiqon A/S Bi- and tri-cyclic nucleoside, nucleotide and oligonucleoide analogues
AU2010312751B2 (en) 2009-10-29 2014-07-24 Osaka University Bridged artificial nucleoside and nucleotide
EP2899197B1 (en) 2012-09-21 2017-03-22 Osaka University Oligonucleotide and artificial nucleoside having guanidine bridge
EP3109254B1 (en) 2014-02-18 2018-04-11 Osaka University Crosslinked nucleoside and nucleotide
ES2893114T3 (es) 2015-02-04 2022-02-08 Bristol Myers Squibb Co Métodos para seleccionar moléculas terapéuticas
AU2018354195A1 (en) 2017-10-23 2020-06-04 Prevail Therapeutics, Inc. Gene therapies for neurodegenerative disease
JP7441523B2 (ja) 2019-02-01 2024-03-01 国立大学法人大阪大学 5’位修飾ヌクレオシドおよびそれを用いたヌクレオチド
TWI910261B (zh) 2020-11-06 2026-01-01 日商住友製藥股份有限公司 Rps25基因之表現及/或功能調節劑
EP4335859A4 (en) 2021-05-06 2025-07-30 Luxna Biotech Co Ltd METHOD FOR DESIGNING AN OLIGONUCLEOTIDE HAVING REDUCED CENTRAL TOXICITY

Also Published As

Publication number Publication date
JPWO2024257847A1 (cg-RX-API-DMAC7.html) 2024-12-19
CN121311591A (zh) 2026-01-09
EP4729616A1 (en) 2026-04-22
WO2024257847A1 (ja) 2024-12-19

Similar Documents

Publication Publication Date Title
US20220143064A1 (en) Tau antisense oligomers and uses thereof
US20180023081A1 (en) Lna oligonucleotides with alternating flanks
US20180312839A1 (en) Methods and compositions for increasing smn expression
CN112424353A (zh) α-突触核蛋白反义寡核苷酸及其用途
CN112912500A (zh) 用于调节atxn2表达的寡核苷酸
CN111819283A (zh) 靶向α-突触核蛋白的反义寡核苷酸及其用途
CN112567033A (zh) 用于调节Tau表达之寡核苷酸
CA3144063A1 (en) Ppm1a inhibitors and methods of using same
TWI910261B (zh) Rps25基因之表現及/或功能調節劑
JP2021514182A (ja) Tmem106b発現を調節するためのオリゴヌクレオチド
US20250376687A1 (en) Compositions and methods to treat neurological diseases
EP4729616A1 (en) Antisense oligonucleotide capable of regulating expression and/or function of rps25 gene
EP4349987A1 (en) Antisense nucleic acid
HK40131699A (en) Antisense oligonucleotide for modulating expression and/or function of rps25 gene
ITMI20012367A1 (it) Oligonucleotidi antisenso che regolano l'espressione del gene antiapoptotico bcl-2
HK40097491A (en) Regulator for expression and/or function of rps25 gene
WO2026048784A1 (ja) Atxn7遺伝子の発現及び/又はその機能を調節するアンチセンス核酸
WO2021187540A1 (ja) Scn1a遺伝子の発現及び/又は機能調節剤
US20250136990A1 (en) Antisense oligonucleotides targeting adenosine kinase
WO2025128816A1 (en) Methods of modulating expression of ube3a gene
WO2024257848A1 (ja) 遅発性中枢毒性が低減されているアンチセンスオリゴヌクレオチドの設計方法、及びその製造方法
WO2026009916A1 (ja) 2本鎖オリゴヌクレオチド
HK40106720A (en) Antisense nucleic acid
HK40039999A (en) Alpha-synuclein antisense oligonucleoties and uses thereof
HK40043583A (en) Oligonucleotides for modulating atxn2 expression